Premium
Curcumin Targeted, Polymalic Acid‐Based MRI Contrast Agent for the Detection of Aβ Plaques in Alzheimer's Disease
Author(s) -
Patil Rameshwar,
Gangalum Pallavi R.,
Wagner Shawn,
PortillaArias Jose,
Ding Hui,
Rekechenetskiy Arthur,
Konda Bindu,
Inoue Satoshi,
Black Keith L.,
Ljubimova Julia Y.,
Holler Eggehard
Publication year - 2015
Publication title -
macromolecular bioscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 105
eISSN - 1616-5195
pISSN - 1616-5187
DOI - 10.1002/mabi.201500062
Subject(s) - curcumin , gadolinium , in vivo , magnetic resonance imaging , mri contrast agent , ex vivo , alzheimer's disease , chemistry , medicine , pathology , biochemistry , disease , in vitro , biology , radiology , microbiology and biotechnology , organic chemistry
Currently, there is no gadolinium‐based contrast agent available for conventional magnetic resonance imaging (MRI) detection of amyloidal beta (Aβ) plaques in Alzheimer's disease (AD). Its timely finding would be vital for patient survival and quality of life. Curcumin (CUR), a common Indian spice effectively binds to Aβ plaques which is a hallmark of AD. To address this binding, we have designed a novel nanoimaging agent (NIA) based on nature‐derived poly(β‐ l ‐malic acid) (PMLA) containing covalently attached gadolinium–DOTA(Gd–DOTA) and nature‐derived CUR. The all‐in‐one agent recognizes and selectively binds to Aβ plaques and is detected by MRI. It efficiently detected Aβ plaques in human and mouse samples by an ex vivo staining. The method can be useful in clinic for safe and noninvasive diagnosis of AD.